BIOGRAPHY
Stuart Marsh is the Chief Growth Officer of Cannim, a rapidly expanding leader in the global medical cannabis industry. Over the last 6 years, Marsh has been instrumental in driving Cannim’s international expansion. From their head office in Sydney Australia, Cannim now operates in Canada, UK, Australia, Europe and the US.
With a background in alcohol and innovation, Marsh uses his experience to bring this exciting new medicinal approach to patients around the world. Working closely with local health care practitioners and listening carefully to patient experiences, Cannim is using research and technology to put in place programs that ensure doctors can guide their patients to the most appropriate cannabis based medicines for their needs.
Leading a team of dedicated experts through this rapidly expanding and evolving industry, Cannim has created a close-knit, family-style approach as a key component of its success, with Marsh playing a crucial role in integrating this culture across all of Cannim’s international teams.
Together with CEO John Worton, Marsh is setting the stage for a revolutionary business model that blends a patient centric focus with technology —unprecedented in the cannabis industry. His operational expertise continues to be vital as Cannim navigates its rapid international growth and cements its reputation as a leader in the burgeoning medical cannabis industry.
ABOUT CANNIM
Founded in 2017 and based in Sydney, Australia, Cannim was established to bring the benefits of medicinal cannabis to the world. At a time when cannabis was still heavily stigmatized and cultivation considered more of an art than a science, Cannim built its foundation on three core pillars: Safety, Science, and Scale. The company’s mission was to demonstrate that cannabis is a legitimate medicine, consistently developed to pharmaceutical standards, and capable of reaching a broad audience of patients in need.
Cannim sources cannabis products from around the globe and has developed a robust network of EU GMP-certified manufacturers. This global reach allows the company to offer a wide variety of cannabis-based products and services, delivering relief to patients in many forms.
As a pioneer in the medicinal cannabis industry, Cannim is leading the charge in advancing cannabis as a reputable medicine. The company is at the forefront of research and education, exploring the effects of cannabis on a wide range of medical conditions. With an ever-growing user base, Cannim continues to scale its operations to meet the increasing demand while maintaining a commitment to patient access and fair pricing. Through innovation in product development and patient care, Cannim is shaping the future of medicinal cannabis and ensuring those in need receive the highest quality treatment when they need it.
